Displaying 1-4 of 4 key documents
Source: Working Group on Clinical Trials and Regulatory Pathways | November 2011
This report provides policy recommendations to help deliver safer and cheaper medical products to people suffering from neglected diseases in developing countries, where they are needed the most.
Although more drugs and vaccines are reaching late-stage clinical development, says the report, they are held back by a lack of funding to support clinical trials, as well as clinical research and regulatory capacity in settings where neglected diseases are endemic. This undermines safety and the validity of clinical data.
The report recommends a two-pronged approach to improving the quality and regulation of clinical trials in the developing world: establishing regional regulatory pathways for the oversight of clinical trials, and building quality and cost-efficiency into trial design and implementation. It also recommends practical steps that can be taken by donors, drug and vaccine developers, and regulatory authorities to begin implementing the changes.
Source: Médecins Sans Frontières | May 2011
This report, from medical aid organisation Médecins Sans Frontières, explores the impact of and lessons learned from the use of antiretroviral treatment (ART) for HIV/AIDS since 2000, when it began providing this to people in need of urgent treatment. It presents results of a survey conducted in 16 countries with different prevalence levels of the disease, which together account for 52.5 per cent of the global HIV/AIDS burden, and outlines the progress, strengths and weaknesses of the international response to the disease.
The report provides an overview of key treatment strategies to improve care and reduce its cost for patients and health systems; discusses the impact of decreased donor funding; and suggests policies that can help lower drug costs, for example, or foster innovations for more effective and affordable treatment. Most HIV-prevalent countries still lack the capacity to treat more than 50 per cent of their population in need of ART, or to provide ART in more than 50 per cent of existing facilities — underlining the need for more domestic and external resources.
Source: The Overseas Development Group | July 2003
This report examines the impact of HIV/AIDS on people's livelihoods in rural areas of Africa, China, Central Asia, India and Russia.
The authors consider labour economising technologies, and set out the potential policy options. They conclude that providing anti-retroviral drugs would have an immediate, and a long-term effect on food security and is the only way of ensuring continued access to labour in the rural sector.
Source: WHO | March 2005
This study assesses whether traditional medicine can contribute to more affordable global healthcare. It uses flowcharts to map out factors such as healthcare infrastructure and social mores that lead much of the developing world to use traditional medicine, and explains the different medicinal systems in use around the world. The author concludes that traditional medicine is a public health asset, provided it can be sufficiently standardised and verified.